Effects of inflammatory and anti-inflammatory cytokines on the bone (Q37880163)

24 August 2017

1 reference

title

Effects of inflammatory and anti-inflammatory cytokines on the bone (English)

1 reference

24 August 2017

0 references

1

Georg Schett

1 reference

24 August 2017

publication date

25 May 2011

1 reference

European Journal of Clinical Investigation

24 August 2017

published in

1 reference

24 August 2017

volume

41

1 reference

24 August 2017

issue

12

1 reference

24 August 2017

page(s)

1361-1366

1 reference

Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2011.02545.X

A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2011.02545.X

TRANCE (tumor necrosis factor [TNF]-related activation-induced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2011.02545.X

Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2011.02545.X

Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2011.02545.X

Cytokines in the pathogenesis of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2011.02545.X

Osteoclasts and arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2011.02545.X

Excretion of pyridinium crosslinks correlates with disease activity and appendicular bone loss in early rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2011.02545.X

Bone resorption by osteoclasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2011.02545.X

Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2011.02545.X

Osteoprotegerin: a novel secreted protein involved in the regulation of bone density

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2011.02545.X

OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2011.02545.X

Tumor necrosis factor alpha-mediated joint destruction is inhibited by targeting osteoclasts with osteoprotegerin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2011.02545.X

Osteoprotegerin reduces osteoclast numbers and prevents bone erosion in collagen-induced arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2011.02545.X

TRANCE/RANKL knockout mice are protected from bone erosion in a serum transfer model of arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2011.02545.X

Lipopolysaccharide-stimulated osteoclastogenesis is mediated by tumor necrosis factor via its P55 receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2011.02545.X

TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2011.02545.X

RANK signaling is not required for TNFalpha-mediated increase in CD11(hi) osteoclast precursors but is essential for mature osteoclast formation in TNFalpha-mediated inflammatory arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2011.02545.X

Induction of osteoclast-associated receptor, a key osteoclast costimulation molecule, in rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2011.02545.X

Interleukin (IL)-6 induction of osteoclast differentiation depends on IL-6 receptors expressed on osteoblastic cells but not on osteoclast progenitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2011.02545.X

Inhibition of interleukin-6 receptor directly blocks osteoclast formation in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2011.02545.X

Soluble interleukin-6 receptor triggers osteoclast formation by interleukin 6

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2011.02545.X

Glycoprotein 130 regulates bone turnover and bone size by distinct downstream signaling pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2011.02545.X

IL-6, leukemia inhibitory factor, and oncostatin M stimulate bone resorption and regulate the expression of receptor activator of NF-kappa B ligand, osteoprotegerin, and receptor activator of NF-kappa B in mouse calvariae

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2011.02545.X

Interleukin-6 and interleukin-11 support human osteoclast formation by a RANKL-independent mechanism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2011.02545.X

TNF-induced structural joint damage is mediated by IL-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2011.02545.X

Interleukin 18 inhibits osteoclast formation via T cell production of granulocyte macrophage colony-stimulating factor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2011.02545.X

Interleukin-18 (interferon-gamma-inducing factor) is produced by osteoblasts and acts via granulocyte/macrophage colony-stimulating factor and not via interferon-gamma to inhibit osteoclast formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2011.02545.X

Interleukin-33 is expressed in differentiated osteoblasts and blocks osteoclast formation from bone marrow precursor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2011.02545.X

IL-33 shifts the balance from osteoclast to alternatively activated macrophage differentiation and protects from TNF-alpha-mediated bone loss.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2011.02545.X

Interleukin-17 and type 17 helper T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2011.02545.X

Mast cells express IL-17A in rheumatoid arthritis synovium

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2011.02545.X

Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2011.02545.X

Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction, and bone erosion

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2011.02545.X

IL-23 inhibits osteoclastogenesis indirectly through lymphocytes and is required for the maintenance of bone mass in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2011.02545.X

IL-12 alone and in synergy with IL-18 inhibits osteoclast formation in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2011.02545.X

IL-23 induces receptor activator of NF-kappaB ligand expression on CD4+ T cells and promotes osteoclastogenesis in an autoimmune arthritis model

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2011.02545.X

M-CSF mediates TNF-induced inflammatory osteolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2011.02545.X

GM-CSF and IL-4 induce dendritic cell differentiation and disrupt osteoclastogenesis through M-CSF receptor shedding by up-regulation of TNF-alpha converting enzyme (TACE).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2011.02545.X

Inhibition of T cell-dependent and RANKL-dependent osteoclastogenic processes associated with high levels of bone mass in interleukin-15 receptor-deficient mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2011.02545.X

Interleukin 4 inhibits murine osteoclast formation in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2011.02545.X

Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: A twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2011.02545.X

RANKL maintains bone homeostasis through c-Fos-dependent induction of interferon-β

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2011.02545.X

T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-γ

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2011.02545.X

10.1111/J.1365-2362.2011.02545.X

21 January 2018

Identifiers

DOI

1 reference

24 August 2017

1 reference